Nocturnal Asthma: Definition, Mechanisms and Treatment1

2015 ◽  
pp. 498-504
Author(s):  
D. C. Flenley
Keyword(s):  
Nocturnal Asthma

Preparation and In Vitro Evaluation of Resealed Erythrocytes as A New Trend in Treatment of Asthma

2016 ◽  
Vol 6 (3) ◽  
Author(s):  
Mohammed Ibrahim ◽  
Alaa Zaky ◽  
Mohsen Afouna ◽  
Ahmed Samy
Keyword(s):  
In Vitro Release ◽  
Human Erythrocytes ◽  
The Body ◽  
Blood Levels ◽  
Time Interval ◽  
Burst Release ◽  
Prolonged Release ◽  
Nocturnal Asthma ◽  
Carrier Erythrocytes

Carrier erythrocytes are emerging as one of the most promising biological drug delivery systems investigated in recent decades. Beside its biocompatibility, biodegradability and ability to circulate throughout the body, it has the ability to perform extended release system of the drug for a long period. The ultimate goal of this study is to introduce a new carrier system for Salbutamol, maintaining suitable blood levels for a long time, as atrial to resolve the problems of nocturnal asthma medication Therefore in this work we study the effect of time, temperature as well as concentration on the loading of salbutamol in human erythrocytes to be used as systemic sustained release delivery system for this drug. After the loading process is performed the carrier erythrocytes were physically and cellulary characterized. Also, the in vitro release of salbutamol from carrier erythrocytes was studied over time interval. From the results it was found that, human erythrocytes have been successfully loaded with salbutamol using endocytosis method either at 25 Co or at 37 Co . The highest loaded amount was 3.5 mg/ml and 6.5 mg/ml respectively. Moreover, the percent of cells recovery is 90.7± 1.64%. Hematological parameters and osmotic fragility behavior of salbutamol loaded erythrocytes were similar that of native erythrocytes. Scanning electron microscopy demonstrated that the salbutamol loaded cells has moderate change in the morphology. Salbutamol releasing from carrier cell was 43% after 36 hours in phosphate buffer saline. The releasing pattern of the drug from loaded erythrocytes showed initial burst release in the first hour followed by a very slow release, obeying zero order kinetics. It concluded that salbutamol is successfully entrapped into erythrocytes with acceptable loading parameters and moderate morphological changes, this suggesting that erythrocytes can be used as prolonged release carrier for salbutamol.

Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma

1999 ◽  
Vol 83 (2) ◽  
pp. 121-126 ◽  
Author(s):  
Richard J. Martin ◽  
Monica Kraft ◽  
Wilfred N. Beaucher ◽  
Frederic Kiechel ◽  
James L. Sublett ◽  
...  
Keyword(s):  
Comparative Study ◽  
Extended Release ◽  
Nocturnal Asthma ◽  
Salmeterol Xinafoate ◽  
Albuterol Sulfate ◽  
Long Acting

Reduction of Nocturnal Asthma by an Inhaled Anticholinergic Drug

CHEST Journal ◽  
1986 ◽  
Vol 90 (4) ◽  
pp. 485-488 ◽  
Author(s):  
C.I. Coe ◽  
Peter J. Barnes
Keyword(s):  
Anticholinergic Drug ◽  
Nocturnal Asthma

scholarly journals Optimized chronomodulated dual release bilayer tablets of fexofenadine and montelukast: quality by design, development, and in vitro evaluation

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Bhupendra Singh ◽  
Geetanjali Saini ◽  
Manish Vyas ◽  
Surajpal Verma ◽  
Sourav Thakur
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Quality By Design ◽  
Immediate Release ◽  
Oral Dosage ◽  
Nocturnal Asthma ◽  
Sustained Release Tablet ◽  
Bilayer Tablets ◽  
Dual Release ◽  
Release Tablet

Abstract Background The conventional oral dosage forms are not effective in dealing with chronopathological conditions, such as nocturnal asthma. Therefore, there is an unmet need to develop a delivery system that can deliver drug as per the chronopharmacology of the diseases. The purpose of the study is to use quality by design (QbD) technique and pulsatile principles for the development of Eudragit-coated dual release bilayer tablets. The dual layer consists of immediate release layer of fexofenadine HCl and sustained release layer of montelukast sodium. Results The quality target product profile of the formulation was developed, and the critical quality attributes were identified. Three-level, three-factor Box-Behnken design was used for the optimization of the bilayer tablets. Based on the design, a total of 13 formulation combinations (F1–F13 and M1–M13) were made having acceptable micromeritic properties. The developed immediate and sustained release layers were evaluated for physicochemical properties. Depending upon the value of the diffusion exponent, the Fickian diffusion mechanism is dominant among immediate and sustained release tablet layers. Response curve for immediate release layer showed that concentrations of sodium starch glycolate and sodium bicarbonate had a negative effect on disintegration time and a positive effect on drug release. For sustained release tablet layer, concentrations of HPMC E 5 LV and magnesium stearate had a significant effect on drug release. The ANOVA and diagnostic plots confirmed the significance and goodness of fit of the used model. Based on desirability plot values, optimized formulation was developed and coated with Eudragit coat. The coated bilayer tablet showed met the requirement of providing an immediate release during the first hour and a sustained release action for a period of more than 8 h after passing the gastric region. Conclusions The formulation can be fruitful in curbing the menace of nocturnal asthma and providing a high degree of patient compliance as the patient will not have to wake up at night to take the medication.

Epidemiology of nocturnal asthma

1988 ◽  
Vol 85 (1) ◽  
pp. 6-8 ◽  
Author(s):  
Margaret Turner-Warwick
Keyword(s):  
Nocturnal Asthma
Sign in / Sign up

Export Citation Format

Share Document